ArticleRSC advances2026
Improving the performance of FAPbI
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In halide perovskite solar cells, the interfaces between the charge-transporting materials and perovskite significantly control the photovoltaic performance of the devices. In this simulation-based work, we introduce fullerene molecules as an interlayer between the front electrode and the perovskite layer to passivate surface defects and mitigate degradation arising from the direct contact between the electrode and the perovskite. Through SCAPS-1D simulation, we suggest that introducing a self-assembled monolayer reduces recombination losses, facilitates charge-carrier extraction, and improves band alignment in perovskite solar cells. We also evaluate the solar cell performance by tuning the perovskite layer thickness, trap-state density, shallow-acceptor density, parasitic resistances, and operating temperature to optimize the photovoltaic designs. The incorporation of this molecular modifier enables the simulation of conventional FAPbI
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.